Sinovac Biotech
Chinese biopharm company
SVA Nasdaq
ISIN AGP8696W1045 SEC CIK 1084201 LEI 529900DOOGH8WKB2WL85
Follow Sinovac Biotech
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $386M | −$198.8M |
| FY24 | $361.4M | $40.7M |
| FY23 | $470.2M | −$13.5M |
| FY22 | $1.5B | $14.5M |
| FY21 | $19.4B | $8.1B |
| FY20 | $510.6M | $110.4M |
| FY19 | $246.1M | $44.9M |
| FY18 | $229.7M | $21.8M |
| FY17 | $174.3M | $25.8M |
| FY16 | $72.4M | −$596K |
| FY15 | $67.4M | −$1.4M |
| FY14 | $62.9M | −$1.5M |
| FY13 | $71.8M | $7.4M |
| FY12 | $49.2M | −$18.7M |
| FY11 | $56.8M | −$844.7K |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 67.9% | −127% | −51.5% |
| FY24 | 61.1% | −139.9% | 11.3% |
| FY23 | 68.8% | −151.9% | −2.9% |
| FY22 | 55.3% | −34.5% | 1% |
| FY21 | 94.9% | 91% | 41.9% |
| FY20 | 86.8% | 42.2% | 21.6% |
| FY19 | 86.8% | 27.9% | 18.3% |
| FY18 | 89.2% | 19.7% | 9.5% |
| FY17 | 88.4% | 26% | 14.8% |
| FY16 | 69.1% | 0.7% | −0.8% |
| FY15 | 72.7% | 5.5% | −2.1% |
| FY14 | 75.4% | 3% | −2.4% |
| FY13 | 71.4% | 13.9% | 10.4% |
| FY12 | 61.2% | −43% | −38.1% |
| FY11 | 62.8% | 5.9% | −1.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$561.1M |
| FY24 | −$152.9M |
| FY23 | −$17.5M |
| FY22 | −$1.1B |
| FY21 | $14.7B |
| FY20 | $351.8M |
| FY19 | $28.4M |
| FY18 | $2.3M |
| FY17 | $47.8M |
| FY16 | −$26.6M |
| FY15 | −$1.1M |
| FY14 | −$21M |
| FY13 | $443K |
| FY12 | −$32.4M |
| FY11 | −$1.5M |
Show the numbers
| Year | Dividends |
|---|---|
| FY25 | $3.5B |
| FY24 | $947M |
| FY23 | $328.1M |
| FY22 | $247.4M |
| FY21 | $1.9B |
| FY20 | $0 |
| FY19 | $0 |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | $802.2K |
| FY11 | $5.9M |
- Sinovac Biotech
- Healthcare median
Show the numbers
| Year | Sinovac Biotech | Healthcare median |
|---|---|---|
| FY25 | −51.5% | −30.6% |
| FY24 | 11.3% | −47% |
| FY23 | −2.9% | −58% |
| FY22 | 1% | −80.4% |
| FY21 | 41.9% | −71.9% |
| FY20 | 21.6% | −62.2% |
| FY19 | 18.3% | −46.3% |
| FY18 | 9.5% | −49.6% |
| FY17 | 14.8% | −45.9% |
| FY16 | −0.8% | −36% |
| FY15 | −2.1% | −38.4% |
| FY14 | −2.4% | −35.5% |
| FY13 | 10.4% | −37.1% |
| FY12 | −38.1% | −29.1% |
| FY11 | −1.5% | −27.9% |